drugset / Trial / NCT00046969

Epoetin Beta in Treating Anemia in Patients With Cervical Cancer

NCT00046969 ↗

Phase 4 Completed 450 enrolled AGO Study Group
RandomizedOpen-labelSupportive care

Summary

RATIONALE: Epoetin beta may stimulate red blood cell production to prevent or control anemia in patients treated with chemotherapy and radiation therapy. PURPOSE: Randomized phase IV trial to determine the effectiveness of epoetin beta in treating anemia in patients who are receiving cisplatin and radiation therapy for stage IIB, stage III, or stage IVA cervical cancer.

Timeline

Start
2002-07
Primary completion
—
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic — Subcutaneous
Background Cisplatin Other / unclassified — Intravenous

Indications